AC Immune Ltd Total Liabilities
AC Immune Ltd total liabilities. Based on the latest financial reports, AC Immune Ltd (ACIU) has total liabilities worth $105.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ACIU asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AC Immune Ltd (2013–2025)
Total liabilities of AC Immune Ltd from 2013 to 2025. This chart illustrates how AC Immune Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore AC Immune Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
AC Immune Ltd Competitors by Total Liabilities
The table below lists competitors of AC Immune Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WildBrain Ltd
TO:WILD
|
Canada | CA$796.01 Million |
|
Genesyslogic
TWO:6104
|
Taiwan | NT$1.74 Billion |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
China | CN¥222.77 Million |
|
Thejo Engineering Limited
NSE:THEJO
|
India | Rs-3.79 Billion |
|
Froch Enterprise Co Ltd
TW:2030
|
Taiwan | NT$7.88 Billion |
|
Mandala Multifinance Tbk
JK:MFIN
|
Indonesia | Rp3.13 Trillion |
|
Z.M.H Hammerman Ltd
TA:ZMH
|
Israel | ILA1.25 Billion |
|
Columbus Circle Capital Corp III Class A Ordinary Shares
NASDAQ:CCCT
|
USA | $259.27K |
Liability Composition Analysis (2013–2025)
This chart breaks down AC Immune Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of AC Immune Ltd.
Liquidity & Leverage Metrics
AC Immune Ltd Total Liabilities Ratios Explained
AC Immune Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AC Immune Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AC Immune Ltd (2013–2025)
The table below shows the annual total liabilities of AC Immune Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $109.49 Million | -7.71% |
| 2024-12-31 | $118.64 Million | +435.13% |
| 2023-12-31 | $22.17 Million | +30.83% |
| 2022-12-31 | $16.95 Million | -42.48% |
| 2021-12-31 | $29.46 Million | +26.66% |
| 2020-12-31 | $23.26 Million | -13.23% |
| 2019-12-31 | $26.81 Million | +41.59% |
| 2018-12-31 | $18.93 Million | +24.77% |
| 2017-12-31 | $15.17 Million | +10.60% |
| 2016-12-31 | $13.72 Million | +54.37% |
| 2015-12-31 | $8.89 Million | +30.15% |
| 2014-12-31 | $6.83 Million | -13.46% |
| 2013-12-31 | $7.89 Million | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more